Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors

被引:45
|
作者
Eggener, Scott E.
Carver, Brett S.
Loeb, Stacy
Kondagunta, G. Varuni
Bosl, George J.
Sheinfeld, Joel
机构
[1] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, Urol Serv, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Oncol Serv, Div Solid Tumor Oncol, New York, NY 10021 USA
[3] Georgetown Univ, Sch Med, Dept Urol, Washington, DC 20057 USA
关键词
retroperitoneal lymph node dissection; salvage therapy; chemotherapy; testicular neoplasms; metastatic;
D O I
10.1002/cncr.22440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Postchemotherapy surgery is an essential component in the management of patients with metastatic germ cell tumors (GCT). The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT. METHODS. By analyzing the institutional prospective surgical database from 1989 to 2004, 71 patients were identified who underwent RPLND after multiple chemotherapy regimens. Clinicopathologic and treatment trends were characterized, and predictors of disease-specific survival (DSS) were evaluated. RESULTS. The histologic findings at RPLND were fibrosis in 36 men (51%), GCT in 20 men (28%), and teratoma in 15 men (21%). Patients who underwent RPLND from 1989 to 1998 (n = 47), compared with patients who under-went RPLND from 1999 to 2004 (n = 24) were more likely to have GCT (36% vs 13%; P = .04). Patients who received taxane-containing chemotherapy regimens as salvage therapy had lower rates of GCT at RPLND (14% vs 42%; P = .01), higher rates of fibrosis (63% vs 39%; P = .04), and similar rates of teratoma (31% vs 33%; P = .9). The 5- and 10-year DSS rates were 74% (95% confidence interval [95% CI], 62-86%) and 70% (95% CI, 56-84%), respectively. Five-year DSS based on worst histology of RPLND and extraretroperitoneal specimens was 87% (95% CI, 75-99%) for fibrosis, 87% for teratoma (95% CI, 63-100%), and 47% for GCT (95% CI, 23-71%; P = .004). On multivariable analysis, retroperitoneal mass >= 5 cm and GCT were predictors of worse DSS (P = .03 and P = .005, respectively). CONCLUSIONS. Taxane-based salvage chemotherapeutic regimens appear to have decreased the rate of GCT at RPLND. The current data support RPLND in select patients after salvage chemotherapy, because a considerable proportion has teratoma or GCT, and the 10-year DSS rate after resection is 70%.
引用
收藏
页码:528 / 535
页数:8
相关论文
共 50 条
  • [31] CLINICAL AND PATHOLOGIC OUTCOMES OF TESTIS CANCER PATIENTS UNDERGOING REDO POST CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION
    Pedrosa, Jose A.
    Beck, Stephen D. W.
    Rice, Kevin R.
    Bihrle, Richard
    Foster, Richard S.
    JOURNAL OF UROLOGY, 2013, 189 (04): : E290 - E291
  • [32] A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only
    Nicolai, N
    Miceli, R
    Artusi, R
    Piva, L
    Pizzocaro, G
    Salvioni, R
    JOURNAL OF UROLOGY, 2004, 171 (01): : 172 - 176
  • [33] PATIENT SELECTION FOR RETROPERITONEAL LYMPH-NODE DISSECTION AFTER CHEMOTHERAPY FOR NONSEMINOMATOUS GERM-CELL TUMORS
    HERR, HW
    TONER, GC
    GELLER, NL
    BOSL, GJ
    EUROPEAN UROLOGY, 1991, 19 (01) : 1 - 5
  • [34] RETROPERITONEAL LYMPH NODE DISSECTION AFTER INDUCTION CHEMOTHERAPY IN METASTATIC TESTICULAR NON-SEMINOMA
    Matveev, V. B.
    Figurin, K. M.
    Volkova, M. I.
    Chernyaev, V. A.
    Mitin, A. V.
    Romanov, V. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 357 - 357
  • [35] RETROPERITONEAL LYMPH NODE DISSECTION AFTER INDUCTION CHEMOTHERAPY IN METASTATIC TESTICULAR NON-SEMINOMA
    Matveev, V. B.
    Figurin, K. M.
    Volkova, M. I.
    Chernyaev, V. A.
    Mitin, A. V.
    ONKOUROLOGIYA, 2010, 6 (01): : 52 - 58
  • [36] Spectrum of Clinicopathologic Findings in Primary and Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Germ Cell Tumors- A Single Institute Experience
    Lenon, Maria Sarah
    Chen, Zhengshan
    Kandukuri, Shivani
    Sherrod, Andy
    Xiao, Guang-Qian
    Amin, Mahul
    Aron, Manju
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 618 - 620
  • [38] Spectrum of Clinicopathologic Findings in Primary and Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Germ Cell Tumors- A Single Institute Experience
    Lenon, Maria Sarah
    Chen, Zhengshan
    Kandukuri, Shivani
    Sherrod, Andy
    Xiao, Guang-Qian
    Amin, Mahul
    Aron, Manju
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 618 - 620
  • [39] Laparoscopic retroperitoneal lymph-node dissection in metastatic nonseminomatous germ-cell tumors
    Nazzani, Sebastiano
    Stagni, Silvia
    Biasoni, Davide
    Catanzaro, Mario
    Macchi, Alberto
    Tesone, Antonio
    Torelli, Tullio
    Darisi, Ruggero
    Lo Russo, Vito
    Colbacchini, Claudia
    Lanocita, Rodolfo
    Cascella, Tommaso
    Claps, Melanie
    Giannatempo, Patrizia
    Zimatore, Matteo
    Cattaneo, Laura
    Montanari, Emanuele
    Salvioni, Roberto
    Nicolai, Nicola
    EJSO, 2023, 49 (01): : 257 - 262
  • [40] Laparoscopic Retroperitoneal Lymph Node Dissection After Chemotherapy for Nonseminomatous Testicular Germ-Cell Tumor at a Single Center
    Shiota, Masaki
    Tanegashima, Tokiyoshi
    Tsukahara, Shigehiro
    Mutaguchi, Jun
    Goto, Shunsuke
    Kobayashi, Satoshi
    Matsumoto, Takashi
    Eto, Masatoshi
    ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 2025, 18 (01)